Home > Pulmonology > NLC 2022 > Interstitial Lung Diseases (ILD) > Rheumatoid arthritis-associated ILD

Rheumatoid arthritis-associated ILD

Presented By
Dr Phuong Phuong Diep, Oslo University Hospital, Norway
Conference
NLC 2022
Doi
https://doi.org/10.55788/20fe5496
Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is a largely under-diagnosed, serious manifestation of RA which accounts for a high mortality rate in affected patients. In recent years, more insight has been obtained regarding triggers, risk factors, and underlying mechanisms enabling more effective treatment of the condition. Dr Phuong Phuong Diep (Oslo University Hospital, Norway) explained that data on the prevalence of ILD in RA (RA-ILD) widely vary – partly attributable to underdiagnosis. The lifetime risk of developing RA-ILD for RA patients is 3.6% and it appears that the MUC5B promoter variant is a strong risk factor. Patients with RA harbouring MUC5B have an increased lifetime risk of developing ILD of 16.8% (95% CI 13.1–20.2) versus 6.1% (95% CI 5.0–7.2) for those without MUC5B. The difference between these risks starts to become evident when patients reach the age of 65 years, with men being more at risk than women [1]. Bas...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on